Tenaya Therapeutics publica dados do RIDGE-1 sobre a terapia gênica TN-401

17 de maio de 2026

Reportado por IA

A Tenaya Therapeutics, Inc. divulgou um conjunto de slides em 17 de maio de 2026, cobrindo os resultados de seu estudo de Fase Ib/II RIDGE-1 sobre a terapia gênica TN-401. A apresentação foca no tratamento para cardiomiopatia arritmogênica do ventrículo direito associada ao PKP2.

O conjunto de slides foi emitido pela empresa em conexão com a revisão de dados clínicos. Ele fornece detalhes sobre o estudo em andamento do candidato à terapia gênica sob o ticker TNYA na NASDAQ. Nenhum resultado adicional ou número de participantes foi especificado nos materiais divulgados.

Health ministry panel conditionally approves iPS cell products

20 de fevereiro de 2026 Reportado por IA Imagem gerada por IA

A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

Inovio Pharmaceuticals held its first-quarter 2026 earnings call on May 13 to discuss financial results for the period ended March 31 and provide updates on its DNA medicines platform.

ProQR Therapeutics presents at TIDES USA 2026

15 de maio de 2026 Reportado por IA

ProQR Therapeutics N.V. published its slide deck for a presentation at the TIDES USA 2026 conference. The materials were released on May 15, 2026, in connection with the company's Q1 earnings summary from May 12.

Saúde

Single-dose zilebesiran as add-on therapy lowers systolic blood pressure in KARDIA-2 trial

Negócios

Intellia reports strong phase iii results for hae treatment

Ásia

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

ARS Pharmaceuticals reports strong start to 2026 in earnings call

ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.

CK Life unit Sequencio eyes China fast track for cancer vaccines

29 de março de 2026 Reportado por IA

Sequencio, a new Hong Kong unit of CK Life Sciences, is advancing about 20 cancer vaccine projects via China's faster pathway to human trials. CK Life Sciences vice-president and chief scientific officer Dr Melvin Toh Kean-meng said the firm plans investigator-initiated trials next year.

Gene therapy restores hearing in patients born deaf

A single injection of gene therapy has significantly improved hearing in all ten patients born with a genetic form of deafness, according to a new study. Researchers delivered a working copy of the OTOF gene into the inner ear, with most patients regaining hearing within one month. The treatment, tested in China, proved safe and effective across ages from one to 24.

USC-led trial tests dopamine-producing stem cell implants for Parkinson’s

20 de fevereiro de 2026 Reportado por IA Verificado

Doctors at Keck Medicine of USC are implanting lab-grown, dopamine-producing cells into the brains of people with Parkinson’s disease in an early-stage clinical trial that will enroll up to 12 participants across three U.S. sites.

sábado, 16 de maio de 2026, 00:33h

Tenaya Therapeutics publica dados do RIDGE-1 sobre a terapia gênica TN-401

Artigos relacionados

Health ministry panel conditionally approves iPS cell products

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

ProQR Therapeutics presents at TIDES USA 2026

Single-dose zilebesiran as add-on therapy lowers systolic blood pressure in KARDIA-2 trial

Intellia reports strong phase iii results for hae treatment

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

ARS Pharmaceuticals reports strong start to 2026 in earnings call

CK Life unit Sequencio eyes China fast track for cancer vaccines

Gene therapy restores hearing in patients born deaf

USC-led trial tests dopamine-producing stem cell implants for Parkinson’s

Caribou Biosciences presents car-t updates at healthcare conference

Cytek Biosciences holds first quarter 2026 earnings call

Syntara reports positive FDA feedback on amsulostat trial

Engineered antibody shrinks tumors body-wide in early cancer trial

Roche shares decline after giredestrant trial fails endpoint

Evaxion reports improved 2025 financials and transformational clinical progress

Japan's ministry approves world's first iPS cell treatments for heart failure and Parkinson's

Sarepta Therapeutics holds Q4 2025 earnings call

AbCellera Biologics publishes Q4 2025 earnings call presentation

Japan panel approves two iPS-derived drugs in world first

Este site usa cookies